Suppr超能文献

靶向内质网的光动力仿生脂质体增强三阴性乳腺癌的联合免疫治疗

Photodynamic Biomimetic Liposomes Targeted to the Endoplasmic Reticulum Enhance Combined Immunotherapy for Triple-Negative Breast Cancer.

作者信息

Li Tianyang, Meng Haimei, Huang Xinfeng, Yu Qin, Sheng Sizhe, Jiang Yufei, Ren Fei

机构信息

Department of Pharmacy, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, China.

First clinical medicine college, Southern Medical University, Guangzhou, Guangdong 510515, China.

出版信息

ACS Appl Mater Interfaces. 2025 Apr 30;17(17):25112-25127. doi: 10.1021/acsami.5c03687. Epub 2025 Apr 21.

Abstract

Cancer immunotherapies, such as immune checkpoint inhibitors, have advanced rapidly and achieved notable success, yet they face significant challenges due to poor response rates and immune-related adverse effects, particularly in cases of triple-negative breast cancer (TNBC). Photodynamic therapy (PDT) can initiate immunogenic cell death (ICD) by inducing endoplasmic reticulum (ER) stress, thereby enhancing the effectiveness of tumor immunotherapy. Herein, we develop potent PDT biomimetic liposomes (PB Lipo) locating the ER to realize a synergistic immuno-photodynamic treatment. The PB Lipo is prepared using the optimal ratios of the phospholipids in the ER membrane. It is then loaded with indocyanine green (ICG), a photosensitizer approved for clinical use. PB Lipo has the unique ability to accumulate in the ER via membrane fusion, leading to severe ER stress when exposed to near-infrared (NIR) laser light, thus intensifying ICD. In combination with the antiprogrammed death-ligand 1 (PD-L1) antibody (αPD-L1), PB Lipo significantly improves efficiency against tumors in xenograft TNBC models. As a result, our combined treatment enhances mature dendritic cells, activates CD4 T and CD8 T cells, and promotes the secretion of cytotoxic cytokines. Collectively, our findings reveal that PB Lipo-mediated PDT presents a viable approach for effectively targeting the ER and enhancing ICD, thereby boosting antitumor efficacy in TNBC.

摘要

癌症免疫疗法,如免疫检查点抑制剂,发展迅速并取得了显著成功,但由于应答率低和免疫相关不良反应,尤其是在三阴性乳腺癌(TNBC)病例中,它们面临着重大挑战。光动力疗法(PDT)可通过诱导内质网(ER)应激引发免疫原性细胞死亡(ICD),从而提高肿瘤免疫治疗的效果。在此,我们开发了定位在内质网的高效光动力疗法仿生脂质体(PB脂质体),以实现免疫-光动力协同治疗。PB脂质体是使用内质网膜中磷脂的最佳比例制备的。然后将其装载上已获临床批准的光敏剂吲哚菁绿(ICG)。PB脂质体具有通过膜融合在内质网中积累的独特能力,在暴露于近红外(NIR)激光时会导致严重的内质网应激,从而增强ICD。与抗程序性死亡配体1(PD-L1)抗体(αPD-L1)联合使用时,PB脂质体显著提高了异种移植TNBC模型中对肿瘤的治疗效果。结果,我们的联合治疗增强了成熟树突状细胞,激活了CD4 T细胞和CD8 T细胞,并促进了细胞毒性细胞因子的分泌。总的来说,我们的研究结果表明,PB脂质体介导的光动力疗法是一种有效靶向内质网并增强ICD的可行方法,从而提高TNBC的抗肿瘤疗效。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验